Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma

• Main Authors: M. K. Ramirez‐Fort (Author), B. Meier‐Schiesser (Author), K. Lachance (Author), S. S. Mahase (Author), C. D. Church (Author), M. J. Niaz (Author), H. Liu (Author), V. Navarro (Author), A. Nikolopoulou (Author), D. V. Kazakov (Author), E. Contassot (Author), D. P. Nguyen (Author), J. Sach (Author), L. Hadravsky (Author), Y. Sheng (Author), S. T. Tagawa (Author), X. Wu (Author), C. S. Lange (Author), L. E. French (Author), P. T. Nghiem (Author), N. H. Bander (Author)
• Format: Book
• Published: Wiley, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Backgrounds Folate Hydrolase‐1 (FOLH1; PSMA) is a type II transmembrane protein, luminally expressed by solid tumour neo‐vasculature. Monoclonal antibody (mAb), J591, is a vehicle for mAb‐based brachytherapy in FOLH1+ cancers. Brachytherapy is a form of radiotherapy that involves placing a...